Acadia Pharmaceuticals | ACAD - PE Price to Earnings


Acadia Pharmaceuticals reported 9.52 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
ALKERMES 262.4 126.59 Sep/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Biogen 29.15 5.92 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Cara Therapeutics 0.49 27.28 Mar/2026
Corcept Therapeutics 86.2 102.04 Sep/2026
Eisai 30.24 3.68 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Incyte 54.54 40.08 Sep/2026
J&J 25.86 3.57 Sep/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 83.17 61.07 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Prothena 22.11 11.37 Mar/2022
PTC Therapeutics 8.76 0 Jun/2026
Sarepta Therapeutics 32.09 22.66 Sep/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023
Vertex Pharmaceuticals 29.35 1.3 Sep/2026